Skip to main content

Table 4 Quantitative parameters of the background and lesions in the exploration cohort

From: Optimizing acquisition times for total-body positron emission tomography/computed tomography with half-dose 18F-fluorodeoxyglucose in oncology patients

Measurement

G15

G8

G5

G3

G2

G1

Liver SUVmax

3.00 ± 0.52

2.98 ± 0.47

3.09 ± 0.49

3.19 ± 0.50*

3.28 ± 0.53*

3.53 ± 0.60*

Liver SD

0.084 ± 0.063

0.124 ± 0.055

0.166 ± 0.070*

0.198 ± 0.072*

0.236 ± 0.074*

0.317 ± 0.100*

Liver SNR

40.98 ± 15.48

26.22 ± 12.19

19.02 ± 6.89*

15.70 ± 5.79*

13.16 ± 5.25*

9.66 ± 3.56*

Liver COV

0.030 ± 0.023

0.046 ± 0.019

0.061 ± 0.025*

0.072 ± 0.025*

0.086 ± 0.027*

0.114 ± 0.033*

Mediastinal SUVmax

2.27 ± 0.37

2.30 ± 0.37

2.33 ± 0.40

2.41 ± 0.43*

2.49 ± 0.45*

2.61 ± 0.50*

Mediastinal SD

0.118 ± 0.049

0.144 ± 0.047*

0.154 ± 0.039*

0.171 ± 0.045*

0.196 ± 0.054*

0.249 ± 0.083*

Lesion SUVmax

9.99 ± 7.94

11.60 ± 9.82

11.68 ± 9.92

12.01 ± 10.25*

12.06 ± 10.23*

12.27 ± 10.42*

Lesion SUVpeak

8.27 ± 6.46

9.01 ± 7.40

8.99 ± 7.36

9.01 ± 7.41

9.07 ± 7.42

8.98 ± 7.51

TBR

3.65 ± 3.11

4.39 ± 3.93*

4.39 ± 3.96*

4.51 ± 4.13*

4.51 ± 4.09*

4.51 ± 4.06*

  1. The measured sample sizes for the background and lesion were 46 and 56, respectively
  2. SUVmax maximum standardized uptake value; SD standard deviation; SNR signal-to-noise ratio; COV coefficient of variation; SUVpeak peak standardized uptake value; TBR tumor-to-background ratio.
  3. Data are presented as mean ± standard deviation (mean ± SD)
  4. *Significant difference in comparison with the control group (G15), p < 0.05